[{"orgOrder":0,"company":"Theranexus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Phase I","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theranexus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theranexus \/ Not Applicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masupirdine","moa":"5-HT6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Not Applicable"},{"orgOrder":0,"company":"ICURE PHARM, INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"ICURE PHARM, INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"ICURE PHARM, INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ICURE PHARM, INC \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"KemPharm \/ Corium","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Corium"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"ACh","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masupirdine","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Donepezil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : ADLARITY (donepezil transdermal system) developed by Corium, is the first and only U.S. FDA approved once-weekly, donepezil transdermal system for patients with mild, moderate and severe dementia of the Alzheimer's type.

                          Brand Name : Adlarity

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 12, 2023

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...

                          Brand Name : Adlarity

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 10, 2023

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Lotus Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.

                          Brand Name : SUVN-502

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 11, 2023

                          Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Cognic (donepezil) is a transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology...

                          Brand Name : Cognic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 19, 2023

                          Lead Product(s) : Donepezil,Memantine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The results of Study 419 did not show statistically significant difference in efficacy between placebo and Aricept (donepezil hydrochloride) groups at time of final analysis in primary endpoint, CIBIC-plus comprehensive assessment.

                          Brand Name : Aricept

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 29, 2022

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. Donepezil is the most prescribed medication in a class of Alzheimer's drugs known as acetylcholinesterase inhibitors.

                          Brand Name : Adlarity

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 19, 2022

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KemPharm is due to receive the fee, within 30 days following FDA approval of ADLARITY, pursuant to a master development services agreement entered into with Corium in July 2020, under which KemPharm provided development related to Corium’s resubmission...

                          Brand Name : Adlarity

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 16, 2022

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Corium

                          Deal Size : $2.0 million

                          Deal Type : Agreement

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The approval of ADLARITY (donepezil transdermal system) reinforces the value of Corium's innovative CORPLEX technology, our CNS expertise, and our mission to deliver solutions that transform care for the Alzheimer's community and others impacted by CNS d...

                          Brand Name : Adlarity

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 14, 2022

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 16, 2021

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The ADLARITY transdermal patch is constructed to be worn for seven days with consistent adhesion, a delivery method that avoids the difficulties associated with daily delivery of an oral medication for patients with significant memory problems.

                          Brand Name : Adlarity

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 12, 2021

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank